Drug Discovery.pre 2026 03 01

Artificial Intelligence • Gene Therapy • Radioligand Theranostics

🤖 Artificial Intelligence

EU AI Act: Commission Publishes Article 6 Implementation Guidelines Ahead of August 2026 High-Risk Deadline

The European Commission released guidelines by the 2 Feb 2026 deadline specifying practical implementation of post-market monitoring for AI systems. Full high-risk AI obligations and enforcement with fines begin 2 Aug 2026, a key compliance milestone for medical device and clinical AI developers.

Regulatory artificialintelligenceact.eu — Implementation Timeline

Stanford–Harvard ARISE Network Publishes Inaugural State of Clinical AI Report 2026

Comprehensive review finds >1,200 FDA-cleared AI medical tools. AI excels at prediction at scale but shows brittle diagnostic reasoning under real-world uncertainty. Report calls for prospective trials, workflow-aware design, and explicit harm measurement for patient-facing AI in 2026.

Journal / Report arise-ai.org — State of Clinical AI Report 2026

FDA Relaxes Clinical Decision Support Software Guidance, Easing AI Market Entry

Updated FDA guidance (6 Jan 2026) allows single-output clinical decision support AI to enter market without premarket review if criteria are met. Also removes prior restriction on risk-score–generating software, widening the regulatory pathway for AI-assisted diagnostics and treatment planning.

Regulatory mwe.com — FDA Loosens the Reins

🧬 Gene Therapy

FDA Issues Complete Response Letter for RGX-121 Gene Therapy for Hunter Syndrome (MPS II)

On 7 Feb 2026, FDA declined to approve REGENXBIO's RGX-121, citing concerns about eligibility criteria distinguishing neuronopathic vs. attenuated disease, comparability of external natural-history controls, and CSF HS D2S6 as surrogate endpoint. Company plans Type A meeting and BLA resubmission.

Regulatory prnewswire.com — REGENXBIO Regulatory Update

Boehringer Ingelheim Halts Inhaled Lentiviral Gene Therapy for Cystic Fibrosis

Phase 1/2 Lenticlair 1 trial of BI 3720931 discontinued after primary readout (3 Feb) showed no efficacy in five enrolled CF patients, despite acceptable safety. Joins Arcturus mRNA and Vertex/Moderna setbacks, underscoring the difficulty of inhaled gene delivery to airway epithelia.

Company PR fiercebiotech.com — Boehringer axes gene therapy

Eli Lilly Acquires Orna Therapeutics for Up to $2.4 Billion — In Vivo CAR-T via Circular RNA

Announced 9 Feb 2026. Orna's platform uses circular RNA + LNPs to generate CAR-T cells in vivo, bypassing ex-vivo manufacturing. Lead asset ORN-252 targets CD19+ B-cell autoimmune diseases. Deal signals big-pharma confidence that in-vivo reprogramming could democratise cell therapy access.

Company PR prnewswire.com — Lilly to Acquire Orna

⚛️ Radioligand Theranostics

Inaugural ASTRO Multidisciplinary Radiopharmaceutical Therapy Symposium (17–18 Feb)

First ASTRO-sponsored RPT symposium presented a pooled analysis of 7 RCTs (n=2,526) showing Lu-177 PSMA-617 delivers a 36% relative reduction in progression risk vs. standard therapies in mCRPC. Also revealed a 20-fold increase in RPT Medicare claims 2013–2023, demonstrating rapid national adoption.

Journal / Conference astro.org — RPT Symposium 2026

Starget Pharma Closes $18M Series A for AI-Driven Radioligand Discovery and SSTR3-Targeted Theranostics

Announced 18 Feb. Funds AI-enabled peptide radioligand design and U.S. translational infrastructure. Lead program is a novel SSTR3-targeted theranostic pair for sarcoma, NETs, and melanoma, expanding the RLT target landscape beyond PSMA and SSTR2. Multiple clinical entries planned in 2026.

Company PR PRNewswire via GuruFocus — Starget Pharma Series A

Radioligand Therapy Market Projected to Reach $4.8B by 2030 (CAGR 13.1%)

ResearchAndMarkets report published 19 Feb estimates global RLT cancer therapeutics market at $2.6B in 2025, growing to $4.8B by 2030. Growth driven by Pluvicto/Lutathera commercial expansion, earlier-line use, alpha-emitter pipeline, and widening institutional adoption across community settings.

Secondary Source GlobeNewswire — RLT Market Report

📡 Expert Signals

ASTRO Launches National Radiopharmaceutical Therapy Training Centres

ASTRO's new Authorized User training programme aims to increase the number of physicians certified to deliver RPT safely, directly addressing the workforce bottleneck that limits patient access as RLT moves into earlier lines of therapy and community settings.

Company PR / Society cancerletter.com — ASTRO RPT Training

FDA's CRL for RGX-121 Signals Heightened Scrutiny on Surrogate Endpoints in Gene Therapy

The rejection underscores FDA's growing caution around natural-history external controls and biomarker surrogates for accelerated approval in ultra-rare diseases. This may recalibrate trial design expectations across the gene therapy pipeline, particularly for CNS-targeting AAV programmes.

Regulatory cgtlive.com — FDA CRL for RGX-121

Clinical AI in 2026: "Superhuman on Narrow Tasks, Brittle Under Uncertainty"

The Stanford–Harvard ARISE report identifies a "jagged frontier" in clinical AI where models excel on controlled benchmarks but falter on multi-turn reasoning with incomplete data — the exact conditions clinicians encounter daily. The report predicts more people will receive AI-mediated medical advice than human advice in the US in 2026.

Journal / Report Stanford Medicine — Clinical AI Has Boomed

📰 In Case You Missed It

1. Lyell Immunopharma Begins First-Ever Head-to-Head Phase 3 CAR-T Trial (12 Feb)

PiNACLE-H2H compares dual-targeting CD19/CD20 ronde-cel against approved CD19 CAR-T therapies in ~400 patients with aggressive LBCL. A landmark trial design for the CAR-T field.

Company PR globenewswire.com — Lyell Phase 3

2. Aidoc Secures FDA Clearance for First Comprehensive Foundation-Model AI Triage (Jan 2026)

Single CARE™ foundation model powers 14 acute-condition triage indications from CT scans. Pivotal data: 97% mean sensitivity, 98% specificity, ~10× fewer false alerts than single-condition tools.

Regulatory aidoc.com — FDA Clearance

3. Cleveland Clinic Weston Hospital Launches Theranostics Programme (Feb 2026)

New programme offers PSMA-targeted radioligand therapy for mCRPC and NETs, reflecting the push to extend RPT from academic centres into broader health-system networks.

Company PR consultqd.clevelandclinic.org — Theranostics Program

4. Anthropic Launches Claude for Healthcare; OpenAI Introduces ChatGPT Health (Jan 2026)

Both platforms now integrate personal health records, EHR data, and fitness apps. Claude adds HIPAA-ready tools for prior auth, billing, and clinical trial workflows. Competitive race for health AI is accelerating.

Company PR medcitynews.com — Anthropic Follows OpenAI Into Healthcare

5. 212Pb-PSMA Alpha Therapy: Preclinical Mechanism-of-Action Data Published (AACR)

ADVC001 (212Pb-based PSMA RLT, Phase I/II NCT05720130) shows potent cytotoxicity in PSMA+ cell lines with EC50 values in low kBq/mL range, supporting lead-212 as a viable alpha-emitter for next-gen RLT.

Journal AACR Cancer Research — Abstract B041